Revance Reports Third Quarter 2020 Financial Results and Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Revance Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Revance Therapeutics (RVNC) Misses Q3 EPS by 31c, Revenues Beat

November 9, 2020 5:00 PM EST

Revance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($1.34), $0.31 worse than the analyst estimate of ($1.03).

The third quarter of 2020 marked a significant milestone in the companys history as Revance successfully transitioned to a fully integrated commercial enterprise. I am very pleased with the positive, early market feedback on our RHA® Collection of dermal fillers and HintMD fintech platform. We have assembled a portfolio of differentiated and unique assets for our aesthetics franchise and we believe we have the right... More